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A Comparison of Low-Dose and 
Normal-Dose Gadobutrol in MR
Renography and Renal Angiography
Objective: It has been advocated that a reduced injection volume with highly
concentrated (1 M) contrast material can produce a sharper bolus peak and an
increased intravascular first-pass gadolinium concentration when compared with
the use of a lower concentration (0.5 M). A higher concentration would also cause
a reduction in dose. The purpose of our study was to test the use of a low dose
(0.05 mmol/kg) of gadobutrol in magnetic resonance renography and angiogra-
phy and compare the findings with a dose of 0.1 mmol/kg.
Materials and Methods: One-hundred-thirty-four patients referred for magnetic
resonance angiography for suspected renovascular disease participated in the
study. Contrast enhanced MR renography and angiography were performed after
administration of a bolus of 0.1 mmol/kg or 0.05 mmol/kg gadobutrol in random-
ized patients. The relative signal intensity-time curves of the aorta, peripheral cor-
tex and parenchyma, were obtained. Two radiologists evaluated the angiographic
images and evaluated the quality of angiography.
Results: The signal intensity with a low dose of gadobutrol was significantly
lower in early phases, in the peripheral cortex (for 36, 54, 72 and 90 seconds), the
parenchyma (for 36, 54, 72 seconds) and the aorta (for 18, 36, 54, 72 seconds).
The decreases in the early phase obtained with a low dose of gadobutrol caused
blunter time intensity curves. The difference in the quality scores of the readers
for the angiographic images for the use of the two different doses was not statisti-
cally significant (p > 0.05).
Conclusion: A lower dose of gadobutrol can be used for MR renal angiogra-
phy, but for MR renography the normal dose should be used.
agnetic resonance imaging (MRI) is widely used in the morphologic
assessment of the renal parenchyma and excretory system. It is especially
useful in evaluating renal masses, the prenatal genitourinary system,
urinary obstructions or infections (1). The functional evaluation of kidneys has been of
interest for many years (2 7). A very high percentage of the functional kidney studies
concern renovascular diseases (RVDs). An RVD can be a cause of hypertension and
1 5% of patients with hypertension have a RVD (8, 9). Although rare, diagnosis is
important because RVD is potentially curable. More than 50% of high-grade stenosis
progress to occlusion within two years (10, 11). MR can demonstrate structural and
functional changes and plays an important role in the diagnosis of RVD.
Gadobutrol (Gadovist, Schering, Berlin, Germany) is a gadolinium-based paramag-
netic contrast agent. It is freely filtered by the glomerulus without tubular secretion or
re-absorption. The total plasma clearance of gadobutrol is very close to renal
clearance, so glomerular filtration is the main pathway of elimination (12 14). The
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Mrecommended gadobutrol dose changes depending on the
region of interest (ROI), and ranges from 0.1 to 0.27
mmol/kg (15). The use of a concentration of 1 M,
gadobutrol allows a reduction of the injection volume by
50% as compared with the use of equimolar doses of MR
contrast agents used at a concentration of 0.5 M. It has
been shown that a reduced injection volume can cause a
sharper bolus peak and increased intravascular first-pass
gadolinium concentration (13 18). A relative high
contrast material concentration allows a reduction in
injection volume and results in a sharper bolus peak that is
important for MR angiography and perfusion imaging, but
can cause a signal loss due to the T2* effect (19, 20). A
higher concentration would potentially cause a reduction
in dose. The purpose of this study is to test the use of low
dose (0.05 mmol/kg) of gadobutrol in MR renography and
angiography and compare the findings with the use of a
dose of 0.1 mmol/kg.
MATERIALS AND METHODS
Patients
A total of 134 patients (70 female, 64 male) with a mean
age of 49 years referred for MR angiography for suspected
RVD participated in the study. Patients were divided into
two groups randomly: fifty-seven (43%) patients were
included in the first group and 77 (56%) patients were
included in the second group. The mean patient age was 50
15 years in the first group and 48  16 years in the
second group. No age and sex difference were noted for
patients in either group (p > 0.05). The study was designed
and performed according to the principles of the Helsinki
Declaration. All participants provided informed consent.
Patients were recruited in the study based on an impaired
renal function and/or poorly controlled hypertension.
Patients were excluded from the study when they had a
single functional kidney or when they had bilateral or
unilateral renal atrophy with impossible cortical differenti-
ation as seen in the early phase of contrast-enhanced
images.
MR Imaging
Contrast enhanced MR renography was performed on a
1.5-T Siemens Symphony system (Siemens Medical
Solutions, Erlangen, Germany) using a phased array body
coil. A bolus of 0.1 mmol/kg gadobutrol (Gadovist,
Schering, Berlin, Germany) was administered to 57
patients and a bolus of 0.05 mmol/kg was administered to
77 patients in randomized order. Contrast material was
delivered at 2 mL/second into an antecubital vein using an
infusion pump injector (Misissipi, Ulrich Medizintechnik,
Germany), and nine coronal three-dimensional image
datasets were acquired at baseline, 18, 36, 54, 72, 90, 300,
420 and 540 seconds using a three-dimensional FLASH
(fast low angle shot) sequence (TR = 3.0 msec, TE = 1.2
msec, flip angle = 25 ) (7). The thickness of the slice block
was variable and ranged from 70 to 90 mm, depending
upon the size of patient and the tortuosity of the aorta as
determined by scout examinations. A total of 46 54
coronal slices were acquired across the slice block, generat-
ing an objective slice thickness of 1.63 mm. The field of
view (FOV) was also variable, and ranged from 257 to 512
mm, depending upon the size of patient. The scan time was
restricted to 18 seconds to minimize respiratory artifacts.
For morphologic assessment, a coronal 2D-trufi (TR = 4.3
msec, TE = 2.1 msec) MR sequence was applied to all
patients before the administration of contrast material. All
examinations were performed with breath holding at the
end of inspiration.
Image Analysis
Images were transferred to a dedicated offline computer
workstation (Leonardo, Siemens Medical Solutions,
Erlangen, Germany). An ROI was placed over the entire
peripheral renal cortex and parenchyma on coronal
images, and a circular ROI was placed covering the full
thickness of the aorta at the level of the renal arteries (Fig.
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Fig. 1. Region of interest includes cortex, parenchyma and aorta.1). Time-intensity curves were generated in each region
(Fig. 4). 
To correct for possible variations in MR signal intensity
among patients due to receiver gain and coil positioning,
measured signal intensities (SIi) were standardized relative
to baseline values prior to contrast material administration
(SI0), according to the calculation (SIi - SI0)/SI0. Cortical
and parenchymal intensity changes in the kidneys and
luminal intensity changes in the aorta by the time were
plotted and the relative signal intensity-time curves were
obtained (5). The long and short axis and parenchymal
thickness of the kidneys were measured in coronal trufi
images.
MR Angiography
MR angiographic images were formed by using the three-
dimensional FLASH sequence used for MR renography
(3.0/1.2, flip angle of 25 , FOV of 257 512 mm, and
rectangular FOV depending on the body habitus). A non-
enhanced image was acquired first to serve as a mask for
subtraction. Image acquisition times were 18 seconds and
the first sequence was used for MR angiographic evalua-
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Fig. 2. MR angiography and MR renographic images of patient after administration of 0.1 mmol/kg gadobutrol.
Fig. 3. MR angiography and MR renographic images of patient after administration of 0.05 mmol/kg gadobutrol.tion. MR angiograms were subjected to a prospective
qualitative analysis based on a segment-by-segment
review. The MR angiography data sets were available on a
workstation that allowed for viewing of the source images,
maximum intensity projections (MIPs), and multiplanar
reconstructions (Figs. 2, 3). Two radiologists assessed the
image quality for arterial visualization. These reviewers
were blinded to the dose of contrast material and patient
identity and clinical history. To achieve objective evalua-
tion, qualitative assessment was performed for nine vessel
segments covering the entire vascular territory of interest.
The vessel segments evaluated were defined as follows:
segment I, the suprarenal abdominal aorta; segment II, the
juxtarenal aorta (including the part approximately 2 cm
above and below the renal arteries and any accessory renal
arteries); segment III, the infrarenal aorta down to the
bifurcation; segments IV, V, the proximal third of the renal
arteries (left and right); segment VI, VII, the middle third
of the renal arteries (left and right); and segments VIII, IX,
the distal third of the renal arteries (left and right).
Accessory renal arteries and proximally bifurcated renal
arteries, if present, were similarly divided into proximal,
middle, and distal segments; and were assessed together
with each principal renal artery segment. For each of the
nine vessel segments, an image quality score between 0
and 2 was assigned, with the scores defined as follows: 0,
poor diagnostic information (impossible to detect or
exclude vascular lesions); 1, moderate diagnostic informa-
tion; 2, adequate diagnostic information. A total image
quality score was determined for each contrast-enhanced
MR angiographic examination as the sum of the numeric
scores assigned to each of the nine vessel segments and
ranged from 0 (poor diagnostic information for all nine
segments) to 18 (adequate diagnostic information for each
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Fig. 4. Relative intensity-time curves of cortex (A), parenchyma (B)
and aorta (C). As seen, significant difference was seen between
two different dose groups in first 72 seconds.
Cof the nine segments) (21). Insufficient studies (a score 
3; one case in the 0.1 mmol/kg-dose group and three cases
in the 0.05 mmol/kg-dose group) were repeated with the
same dose. Only arterial enhancement was assessed; no
scoring was performed for renal venous enhancement.
Image artifacts, if present, were noted, but no specific
scoring for artifacts was performed.
Statistical Analysis
The student t-test was used to compare age and sex,
renal morphologic measurement and relative intensity
values. To compare the total image quality scores of
observers between the two dose groups, the Mann-
Whitney U test was used. The Wilcoxon Signed Ranks test
was used to compare the difference of total image quality
scores between two observers. To analyze the mean and
standard deviation values of the total image quality scores,
descriptive statistics were used. We used the Kappa test to
asses the concordance of the readers in quality assessment
of MR angiography.
RESULTS
No age difference was noted between the two patient
groups. The long and short axis length and parenchymal
thickness of the kidneys showed no differences between
the two groups. The areas and pixel counts in the ROI
drawn to form relative signal intensity-time curves of the
cortex and parenchyma showed no difference. The pixel
count in the aorta showed a significant difference, but
there were no differences in areas (Table 1).
The relative signal intensity with the low dose was signif-
icantly lower in the peripheral cortex for 36, 54, 72 and 90
seconds (Table 2), for the renal parenchyma in 36, 54, and
72 seconds, and for the aorta in 18, 36, 54, and 72 seconds
(Tables 3, 4). These decreases in early phase obtained with
low dose caused a decrease in amplitude of the relative
signal intensity-time curves (Fig. 4).
The quality assessment scores of angiography showed
moderate agreement between the two readers with a
Kappa value of 0.567 (p < 0.001). No statistically signifi-
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Table 2. Relative Intensity Values of Two Dose Groups in Peripheral Cortex
Gadobutrol Dose 0.1 mmol/kg 0.05 mmol/kg
Relative Intensity  P values T
Values by Time in Cortex Mean  SD Mean  SD
018 sec 1.47  1.10 1.24  0.93 0.137 1.494
036 sec* 2.10  0.98 1.59  0.82 < 0.001 3.750
054 sec* 2.05  0.91 1.52  0.75 < 0.001 4.223
072 sec* 1.92  0.83 1.57  1.00 < 0.05 2.255
090 sec* 1.81  0.86 1.52  0.73 < 0.05 2.398
300 sec 1.40  0,64 1.26  0.64 0.154 1.431
420 sec 1.24  0.64 1.15  0.59 0.325 0.986
540 sec 1.03  0.64 1.05  0.55 0.782 0.277
Note. *p < 0.05, SD = standard deviation 
Table 1. Morphologic Measurements of Kidney and Aorta in Two Dose Groups
Gadobutrol Dose 0.1 mmol/kg 0.05 mmol/kg
Morphological Findings Mean  SD Mean  SD
P values T
Vertical diameter (mm) 098  16 100  16 0.450 0.757
Horizontal diameter (mm) 49  8 48  9 0.376 0.888
Parenchyma thickness (mm) 21  4 19  5 0.096 1.673
Pixel count in cortex 1572  412 1621  540 0.551 0.597
Area of cortex (cm
2) 18  6 0036  211 0.531 0.628
Pixel count in parenchyma 2521  812 2775  935 0.077 1.776
Area of parenchyma (cm
2) 28  9 319  10 0.14 2.487
Pixel count in aorta* 175  53 220  66 < 0.05 3.172
Area of aorta (cm
2) 02.3  1.8 03.4  5.6 0.324 0.992
Note. *p < 0.05, SD = standard deviation cant difference between the two dose groups according to
the each reader individually was noted (p > 0.05). The
difference in the total score between the two observers
was significant in the low dose group (p < 0.05) and was
not significant for the normal dose group (p > 0.05) (Table
5).
DISCUSSION
Dynamic MR imaging is a well-known technique that
provides both morphological and functional information
for RVD (2, 4, 22 24). Schoenberg et al. (6, 22) described
that either a normal curve or partial loss of the early
systolic peak in time intensity curves is consistent with a
low grade of stenosis. Complete loss of the early systolic
peak and a decrease of the midsystolic peak indicated
moderate stenosis (50%); a flattened profile with no
systolic peaks was representative of high-grade stenosis.
The neutral gadolinium chelate agent gadobutrol allows
the use of gadolinium concentrations of 1.0 M for
intravenous injection (12). The high concentration provides
increased gadolinium concentrations at the temporal bolus
peak and a sharper bolus profile because of reduced
injection volumes, which can be advantageous for
perfusion imaging and angiography (14, 25, 26). An
intravenous injection of 1.0-M gadobutrol at a dose of up
to 0.1 0.27 mmol/kg in the indication of contrast
enhanced MR angiography is safe and causes no clinically
relevant changes (12, 14, 27). To the best of our
knowledge, no study has reported about the use of low
dose gadobutrol in MR angiography and renography.
In this study, we compared MR angiography and MR
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Table 5. Total Image Quality Scores of Each Observer
between Two Dose Groups 
0.1 mmol/kg   0.05 mmol/kg  
Gadobutrol (n = 57)* Gadobutrol (n = 77)*
P
Observer 1 14.28  3.43 14.33  3.35 0.960
Observer 2 14.11  3.42 14.10  3.31 0.933
P 0.079 0.011
Note. *Data are mean  standard deviation
Table 4. Relative Intensity Values of Two Dose Groups in Aorta
Gadobutrol Dose 0.1 mmol/kg 0.05 mmol/kg
Relative Intensity P values T
Values by Time in Aorta Mean  SD Mean  SD
018 sec* 7.97  3.65 06.6  3.39 < 0.05 2.504
036 sec* 5.35  2.58 3.96  1.45 < 0.001 4.839
054 sec* 4.34  1.78 3.32  1.27 < 0.001 4.565
072 sec* 3.57  1.83 3.03  1.22 < 0.05 2.447
090 sec 2.98  1.72 2.74  1.23 = 0.258 1.133
300 sec 1.96  1.11 1.96  0.85 = 0.974 0.033
420 sec 1.71  1.06 1.67  0.76 = 0.778 0.282
540 sec 1.41  1.05 1.51  0.74 = 0.465 0.732
Note. *p < 0.05, SD = standard deviation 
Table 3. Relative Intensity Values of Two Dose Groups in Parenchyma
Gadobutrol Dose
0.1 mmol/kg 0.05 mmol/kg
Relative
Intensity Values 
P values T
by Time in Parenchyma
Mean  SD Mean  SD
018 sec 1.22  0.91 1.12  0.87 = 0.470 0.725
036 sec* 1.89  0.86 1.50  0.81 < 0.05 3.040
054 sec* 1.97  0.81 1.55  0.78 < 0.05 3.392
072 sec*0 1.91  0.75 1.65  0.82 < 0.05 2.071
090 sec 1.91  0.80 1.71  0.82 = 0.108 1.615
300 sec 1.51  0.60 1.45  0.72 = 0.549 0.600
420 sec 1.36  0.60 1.32  0.67 = 0.707 0.377
540 sec 1.16  0.65 1.21  0.64 = 0.582 0.551
Note. *p < 0.05, SD = standard deviation renography findings of patients where doses of 0.1
mmol/kg and 0.05 mmol/kg gadobutrol were administered.
The mean relative signal intensity-time curves made by
drawing ROI to include peripheral cortex, parenchyma and
aorta showed a lower intensity for the low dose than for
the normal dose group of patients, especially in the first 90
seconds of the study with a duration of 9 minutes. The
early arterial peak in the relative signal intensity-time
curves obtained by renal functional MR imaging is known
to be important in renal arterial stenosis (1, 6, 7, 22, 23).
Although the curves in both groups were almost similar,
early differences can alter dynamic functional evaluation
of the kidneys, especially for renal arterial stenosis,
because of blunt early arterial peeks. 
The relative signal intensity-time curve in the aorta was
significantly higher in 18, 36, 54, 72 seconds for the
regular administered dose of gadobutrol. Theoretically, a
dose of 0.1 mmol/kg would be better for angiography than
a dose of 0.05 mmol/kg because of the higher relative
intensity in the first sequences. The angiographic quality
assessment scores of the two readers showed moderate
agreement with a Kappa value of 0.588 (p < 0.001). The
body habitus, circulatory condition and adaptation to the
technique, especially by breath holding, can affect the
quality of images. In addition, we did not use objective
criteria for quality assessment. All of these cause could be
the reason of the moderate Kappa value. Although there is
a moderate agreement, both readers did not note a differ-
ence in the quality scores between the two dose groups.
The difference of the relative signal intensity in the very
early phase of the aorta did not affect the angiographic
quality scores of the readers.
A lower and blunter early cortical phase in relative signal
intensity-time curves with a low dose may potentially
affect the MR angiography and functional evaluation for
renal arterial stenosis. However, these differences of the
relative signal intensity-time curves did not affect
angiographic quality. A lower dose can be used in renal
angiography alone, but for functional evaluation, the
normal dose should be used. We believe that a low dose
can also be used for renal parenchymal evaluation or
magnetic resonance urography; as the renal parenchyma
and late excretion phases showed no significant difference.
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